Xencor Inc (XNCR) Form 8-K — Oct 26, 2026
$XNCRForm 8-KItems 2.02, 7.01, 8.01, 9.01Filed Oct 26, 2026, 7:50 AM ET0001213900-26-112279Original filing
Xencor reported updated Phase 1 results for XmAb819, a wholly owned ENPP3 x CD3 bispecific, in advanced clear cell renal cell carcinoma at the ESMO Congress, showing confirmed response rates of 30%, 44%, and 45.5% at the 100, 200, and 400 mcg/kg doses respectively. The company selected 400 mcg/kg as the proposed Phase 3 dose, citing a 55% unconfirmed ORR, an 82% six-month PFS Kaplan-Meier estimate, and a median PFS not yet reached, with 45% cORR maintained in heavily pre-treated patients after two or more VEGFR TKIs.
Key figures
- Dcr 400mcg
- 82%
- Cash runway
- into 2029
- Corr 100mcg
- 30%
- Corr 200mcg
- 44%
- Corr 400mcg
- 45.5%
- End of phase1 meeting
- 1H 2027
- Unconfirmed orr 400mcg
- 55%
- Expansion dose patients
- 68
- Grade3plus related teae
- 72.1%
- Six month pfs km 400mcg
- 82%
- Patients enrolled phase1
- 119
- Corr prior 2 vegfr tki subgroup
- 45%
- Tivozanib comparator orr tinivo2
- 10.5%
- Related teae discontinuation rate
- 5.9%
- Corr triple class exposed subgroup
- 35%
- Registration enabling study timing
- by end of 2027
- Tivozanib comparator median pfs months
- 5.4
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.